Developments Pluri completes first phase of placenta-derived biomaterials program Pluri (NASDAQ, TASE: PLUR) has announced the completion of the first phase of its program with closely held Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix- based... January 22, 2026